Fovea Pharma

Fovea Pharma was a French biopharmaceutical company specializing in the development of innovative treatments for ocular diseases, with a primary focus on retinal pathologies. Founded in 2005, the company built a robust pipeline targeting conditions such as retinitis pigmentosa, diabetic macular edema, and age-related macular degeneration. Its research was anchored by the Rod-derived Cone Viability Factor (RdCVF) platform, a neuroprotective approach aimed at preserving cone photoreceptors and preventing blindness. In 2009, Fovea Pharma was acquired by Sanofi-Aventis for approximately €370 million, serving as the foundation for Sanofi's dedicated ophthalmology division. The company's portfolio included both small molecule and biologic candidates in various stages of clinical development.